Australia markets closed

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.7657-0.0023 (-0.30%)
At close: 04:00PM EDT
0.7592 -0.01 (-0.85%)
After hours: 06:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7680
Open0.7800
Bid0.7616 x 100
Ask0.7904 x 100
Day's range0.7550 - 0.7842
52-week range0.6700 - 3.1300
Volume241,936
Avg. volume810,537
Market cap55.744M
Beta (5Y monthly)0.47
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., May 09, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.

  • Business Wire

    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., May 06, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 164,000 shares of its common stock with an exercise price of $0.84 per share, which is equal to the closing price of Kezar’s c

  • Business Wire

    Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., April 08, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted one employee a nonqualified stock option to purchase 12,000 shares of its common stock with an exercise price of $0.93 per share, which is equal to the closing price of Kezar’s common stock on April 1, 2